|Bid||0.00 x 3100|
|Ask||0.00 x 800|
|Day's Range||5.99 - 6.22|
|52 Week Range||3.95 - 6.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.17|
Idera shareholders voted in favor of the deal. The Chester County company will get $6M as a result of the termination.
The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.
Among the companies with shares expected to trade actively in Wednesday's session are Boeing, Ford, American Airlines, Pfizer and Comcast.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...
BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Company’s strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”). Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, said, “We are moving forward executing our standalone strategy with a great deal of confidence in our programs, our pipeline and our ability to drive value for our stockholders. Also, we are on track for a first half of 2019 initiation of a Phase 1 clinical trial for our ALK-2 inhibitor program for treating fibrodysplasia ossificans progressiva, or FOP.
There will be no deal as shareholders of Research Triangle Park-based BioCryst Pharmaceuticals have blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals.
Inc. called off merger plans Tuesday after BioCryst shareholders voted against the proposal, triggering a $6 million penalty to be paid to Idera. Some BioCryst shareholders, including Great Point Partners LLC and RA Capital Management LLC, had publicly objected to the merger plan and noted that they intended to vote against it.
MARKET PULSE Shares of BioCryst Pharmaceuticals Inc. (bcrx) and Idera Pharmaceuticals Inc. (idra) were active in the extended session Tuesday following a brief halt after BioCryst shareholders voted down a merger between the two drug companies.
BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst”) today announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals, Inc. (IDRA) (“Idera”) following the BioCryst stockholders’ failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held today. “We respect and understand the views of our stockholders and are moving forward fully-focused on executing our business plan as a standalone company,” said Jon P. Stonehouse, BioCryst’s President and Chief Executive Officer.
LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40.
RESEARCH TRIANGLE PARK, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has reached agreement on the design of a Phase 3 trial and regulatory requirements for marketing authorization of BCX7353 for Hereditary Angioedema (“HAE”) with the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan.
GREENWICH, Conn. , June 20, 2018 /PRNewswire/ -- Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing ...
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018-- BioCryst Pharmaceuticals, Inc., and Idera Pharmaceuticals, Inc., today announced that they will be presenting at the JMP Securities Life Sciences ...
BioCryst Pharmaceuticals, Inc. (BCRX) (“BioCryst” or the “Company”), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today issued an open letter to stockholders in connection with the Company’s Special Meeting of Stockholders to be held on July 10, 2018. BioCryst’s Special Meeting of Stockholders is scheduled for July 10, 2018. The BioCryst Board of Directors believes this transaction represents a significant opportunity to enhance the value of your investment in BioCryst and unanimously recommends that stockholders vote “FOR” the transaction, which will create a new company to be called Valenscion Incorporated (“Valenscion” or the “combined company”).
RESEARCH TRIANGLE PARK, N.C., May 29, 2018-- BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced the ...
BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the European Medicines Agency’s (“EMA”) Committee for Orphan Medicinal Products (“COMP”) issued a positive opinion on BioCryst’s application for orphan designation of BCX7353 for the treatment of hereditary angioedema (“HAE”). In addition, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) has granted a Promising Innovative Medicine (“PIM”) designation to BCX7353.
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., May 24, 2018-- BioCryst Pharmaceuticals, Inc., and Idera Pharmaceuticals, Inc., today announced that they will be presenting at the Jefferies 2018 Global Healthcare ...
LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX).
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PRTO as the Company's latest news hit the wire. On May 8, 2018, the Company announced that it has extended its long-term contract with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase's active pharmaceutical ingredient (API). Active-Investors.com is currently working on the research report for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), which also belongs to the Healthcare sector as the Company Proteon Therapeutics.
The most recent earnings announcement BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) released in December 2017 showed company earnings became less negative compared to the previous year’s level as a result of recentRead More...
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 26 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...